Akari Therapeutics’ (AKTX) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Friday,Weiss Ratings reports.

A number of other research analysts also recently issued reports on the company. Maxim Group began coverage on Akari Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $1.60 price objective on shares of Akari Therapeutics in a research note on Tuesday, September 9th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.30.

Akari Therapeutics Price Performance

NASDAQ:AKTX opened at $0.74 on Friday. The stock has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $1.08. Akari Therapeutics has a 52-week low of $0.57 and a 52-week high of $3.15.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.